Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
Foamix Pharmaceuticals Ltd. (FOMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/12/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
02/06/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Foamix and Menlo Announce Shareholder Approval of Proposed Merger"
01/14/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Foamix Announces AMZEEQ TM Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S."
01/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Foamix Announces AMZEEQ TM Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne"
12/18/2019 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12/16/2019 8-K Other Events
12/04/2019 8-K Amended merger/acquisition agreement
Docs: "Amendment No. 1 to the Agreement and Plan of Merger, by and among Foamix Pharmaceuticals Ltd., Menlo Therapeutics Inc. and Giants Merger Subsidiary Ltd"
11/12/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
11/07/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "REHOVOT, Israel, and BRIDGEWATER, NJ, November 7, 2019 –"
10/23/2019 8-K Quarterly results
10/18/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "REHOVOT, Israel and BRIDGEWATER, N.J., October 18 th , 2019 --"
10/17/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "U.S. Investor Relations"
09/04/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "U.S. Investor Relations"
08/19/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sales Agreement",
"Foamix Pharmaceuticals Ltd."
08/07/2019 8-K Quarterly results
08/05/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "U.S. Investor Relations"
07/30/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Opinion of Herzog Fox & Neeman",
"Share Purchase Agreement, by and among the Company and Perceptive Life Sciences Master Fund, Ltd",
"Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed"
05/08/2019 8-K Quarterly results
Docs: "Rehovot, Israel, and Bridgewater, NJ, May 7, 2019"
04/11/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "1. General. Successor to and Continuation of 2015 Plan. The Plan is intended as the successor to and continuation of the Company’s 2015 Israeli Share Incentive Plan, as amended from time to time . From and after 12:01 a.m. Eastern Time on the Effective Date, no additional awards will be granted under the 2015 Plan. All Awards granted on or after 12:01 a.m. Eastern Time on the Effective Date will be granted under this Plan. All awards granted under the 2015 Plan will remain subject to the terms of the 2015 Plan. Any shares that would otherwise remain available for future grants under the 2015 Plan as of 12:01 a.m. Eastern Time on the Effective Date will cease to be available under the 2015 Plan at such time. Instead, that number of Shares equal to the 2015 Plan’s Available Reserve will be a...",
"Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan Adopted by the Board of Directors: February 28, 2019 Approved by the Shareholders: April 10, 2019 1. General; Purpose. The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. 2. Administration. The Board will administer the Plan unless and unt..."
03/07/2019 8-K Quarterly results
02/28/2019 8-K Quarterly results
01/24/2019 8-K Appointed a new director
Docs: "Rehovot, Israel, and Bridgewater, NJ – January 23, 2019"
01/03/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/19/2018 8-K Appointed a new director
Docs: "Rehovot, Israel, and Bridgewater, NJ – November 19 2018 – Foamix Pharmaceuticals Ltd. , a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Anthony Bruno to its Board of Directors, replacing Darrell Rigel, M.D. who has resigned from the Board and will become a consultant to the company"
11/07/2018 8-K Quarterly results
Docs: "Rehovot, Israel, November 7, 2018",
"Presentation slides",
"Rehovot, Israel, and Bridgewater, NJ – November 7th, 2018 – Foamix Pharmaceuticals Ltd. , , a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced the topline results from its Phase 3 program evaluating FMX103 1.5% minocycline foam, in the treatment of moderate-to-severe papulopustular rosacea. Studies FX2016-11 and FX2016-12 met both co-primary endpoints of absolute change from baseline in inflammatory lesion count at Week 12, and Investigator Global Assessment treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement from baseline. The safety profile of FMX103 was found to be favorable. Data from study FX2016-13 evaluating the..."
10/01/2018 8-K Quarterly results
09/18/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among Foamix Pharmaceuticals Ltd., and Merrill Lynch, Pierce, Fenner & Smith, Cowen and Company, LLC and Barclays Capital Inc., as representatives of the several underwriters listed in Schedule I thereto",
"Opinion of Herzog Fox & Neeman"
09/12/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Presentation slides",
"Rehovot, Israel, and Bridgewater, NJ – September 11, 2018 – Foamix Pharmaceuticals Ltd. , , a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced the topline results of its third Phase 3 clinical trial of FMX101 for the treatment of moderate-to-severe acne. The study met both co-primary endpoints of absolute change from baseline in inflammatory lesion count at Week 12, and Investigator Global Assessment treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement from baseline. The safety profile of FMX101 was found to be consistent with that determined from the two prior Phase 3 studies . Foamix plans to continue to share data fr..."
06/27/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Rehovot, Israel, and Bridgewater, NJ – June 27, 2018"
05/14/2018 8-K Submission of Matters to a Vote of Security Holders
05/09/2018 8-K Quarterly results
Docs: "Rehovot, Israel, May 8, 2018"
05/07/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Rehovot, Israel, and Bridgewater, NJ – May 7th, 2018"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy